Dramatic rebounds of MS during pregnancy following fingolimod withdrawal
Citation Manager Formats
Make Comment
See Comments
This article has a correction. Please see:

Article Information
- Received January 12, 2017
- Accepted in final form May 11, 2017
- First Published July 27, 2017.
Author Disclosures
- Giovanni Novi, MD,
- Angelo Ghezzi, MD,
- Matteo Pizzorno, MD,
- Caterina Lapucci, MD,
- Fabio Bandini, MD,
- Pietro Annovazzi, MD,
- Giovanni L. Mancardi, MD, PhD and
- Antonio Uccelli, MD, PhD
- Giovanni Novi, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Angelo Ghezzi, MD,
Novartis, advisory board of a trial in pediatric MS
NONE
NONE
Multiple Sclerosis International, no compensation
NONE
NONE
Merck Serono, speaker in a scientific meeting Biogen Idec, speaker in a scientific meeting Novartis, speaker in a scientific meeting Genzyme, speaker in a scientific meeting Teva, speaker in a scientific meeting
Novartis, consulting activity Biogen, consulting activity Mylan, consulting activity Roche, consulting activity
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Matteo Pizzorno, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Caterina Lapucci, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Fabio Bandini, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Pietro Annovazzi, MD,
Dr. Annovazzi served on advisory boards for Novartis, Genzyme, Teva, Roche, Merck-Serono and Biogen
NONE
Dr. Annovazzi received speaking honoraria from Teva Italia, Novartis, Genzyme, Merck-Serono and Biogen
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Giovanni L. Mancardi, MD, PhD and
NONE
NONE
Honoraria for lecturing , travel expenses for attending meetings and finacial support for research from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi- Aventis and Teva Pharmaceuticals
Associate Editor of Neurological Sciences
NONE
NONE
Honoraria for speaking activities from Companies (Biogen Idec, Bayer Schering)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Italian Multiple Sclerosis Society (AISM) Grants 2001-R- 38 and 2002-R-36
NONE
NONE
NONE
NONE
NONE
NONE
- Antonio Uccelli, MD, PhD
Served on the Scientific Advisory Boards for Genetech (2009), Roche 2009- present), Allergan 2009-present
NONE
Received funding for a trip to give a lecture from Athersys (2009)
NONE
NONE
NONE
Received honoraria to give lectures from Biogen Dompe', Serono Symposia, Sanofi Aventis, Tohoku University Graduate School of Medicine.
Received consulting fee from Merck-Serono (2009), Biogen Domp? (2010)
NONE
NONE
NONE
Received grant support from Bayer Schering (2009) and Sanofi Aventis (2009)
Funded as Principal Investigator from Italian Ministry of Health (RF-LIG- 2007-647513) (2008-2010), from the Regione Liguria, Progetto LIMONTE (2009-2010), Ricerca Sanitaria Regionale (2010)
NONE
Funded as Principal Investigator from the Fondazione Italiana Sclerosi Multipla (Progetto Speciale Cellule Staminali (2008-present), Fondazione CARIGE (2008-present)
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI) (N.G., C.L., G.L.M., A.U.), University of Genoa, Italy; Multiple Sclerosis Study Center (A.G., P.A.), Hospital of Gallarate, Italy; San Paolo Hospital (M.P., F.B.), Savona, Italy; and IRCCS AUO San Martino—IST (G.L.M., A.U.), Genoa, Italy.
- Correspondence to Dr. Novi: giovanninovi{at}gmail.com
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Research
Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practiceCarrie M. Hersh, Haleigh Harris, Devon Conway et al.Neurology: Clinical Practice, February 12, 2020 -
Article
Progressive multifocal leukoencephalopathy after fingolimod treatmentJoseph R. Berger, Bruce A. Cree, Benjamin Greenberg et al.Neurology, April 18, 2018 -
Articles
Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MSJ. Kuhle, R. Gosert, R. Bühler et al.Neurology, November 09, 2011 -
Diagnostic and Treatment Challenges
Treating MS after surviving PML: Discrete strategies for rescue, remission, and recovery patient 1From the National Multiple Sclerosis Society Case Conference ProceedingsNidhiben Anadani, Megan Hyland, Roberto Alejandro Cruz et al.Neurology: Neuroimmunology & Neuroinflammation, December 15, 2020